Stay updated on Nivolumab in Resectable Osteosarcoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in Resectable Osteosarcoma Clinical Trial page.

Latest updates to the Nivolumab in Resectable Osteosarcoma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedPage revision updated from v3.6.2 to v3.6.3, indicating a new revision of the study record. This update reflects a newer page version on ClinicalTrials.gov and may include minor corrections or enhancements without altering core study details.SummaryDifference0.0%

- Check15 days agoChange DetectedThe page revision label has been updated from v3.6.0 to v3.6.2, signaling a newer page build.SummaryDifference0.0%

- Check30 days agoChange DetectedNew help/navigation sections were added (How to Read a Study Record, Common Questions, How to Join a Study) and the Intervention/Treatment label formatting updated from Intervention / Treatment, with the revision version changing from v3.5.5 to v3.6.0; the recruitment status now shows No longer looking for participants.SummaryDifference0.4%

- Check37 days agoChange DetectedThe page footer now includes updated branding references to the Moffitt Cancer Center Clinical Trials website and related institution names, along with a 'Helpful Links Provided by' note, and the revision number was updated from v3.5.4 to v3.5.5.SummaryDifference0.2%

- Check44 days agoChange DetectedSponsor branding/navigation items linking to the Moffitt center and its trial resources were removed from the page header/footer, reducing quick access to sponsor-related resources.SummaryDifference0.1%

- Check58 days agoChange DetectedRevision updated from v3.5.3 to v3.5.4 on the page, indicating a software patch with no changes to the study content.SummaryDifference0.0%

Stay in the know with updates to Nivolumab in Resectable Osteosarcoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in Resectable Osteosarcoma Clinical Trial page.